Evidence map›Paper›PMID 42034829›Full record

ArticleScientific reports2026

Dissecting temporal regulation of the TLR4-IL-6 axis using systematic targeted inhibition.

Guilherme A Gouveia, Rob Ter Heine, Manon Kolkman, Annemijn J Arns, Ruben L Smeets, Hans J P M Koenen, Marien I de Jonge

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guilherme A GouveiaDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Community for Infectious Diseases, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Guilherme.Gouveia@radboudumc.nl.
Rob Ter HeineDepartment of Pharmacy, Pharmacology & Toxicology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Manon KolkmanDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Community for Infectious Diseases, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Annemijn J ArnsDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Community for Infectious Diseases, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Ruben L Smeets *Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Community for Infectious Diseases, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Hans J P M Koenen *Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Community for Infectious Diseases, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Marien I de JongeDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Community for Infectious Diseases, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

Horizon 2020 Framework Programme CONSENSE
6 · The paper itself

Abstract

Acute systemic inflammatory disorders, such as cytokine release syndrome or sepsis, remain among the leading causes of mortality. To better understand early inflammatory dynamics, we developed an ex vivo model using human peripheral blood mononuclear cells to study IL-6 release kinetics via the Toll-like receptor 4 pathway. A consistent kinetic profile was observed and described with a mixed-effects model. To further dissect the signaling hierarchy, we investigated the response dynamics of multiple inhibitors targeting the various stages of signaling at different timepoints. The results suggest individual differences with common patterns of IL-6 kinetics and indicate that sustained IL-6 release requires continuous upstream signaling. Furthermore, important feedback mechanisms were identified, with NF-κB and p38 emerging as critical regulators when compared with other members. The translational relevance of our model was further supported and validated by the use of clinically applied drugs, which demonstrated consistent effects with their known clinical activity.

Indexed as

Interleukin-6Signal TransductionToll-Like Receptor 4HumansKineticsLeukocytes, MononuclearNF-kappa Bp38 Mitogen-Activated Protein KinasesIL6 protein, humanInterleukin-6NF-kappa Bp38 Mitogen-Activated Protein KinasesTLR4 protein, humanToll-Like Receptor 4Acute InflammationCytokinesInhibitionKinetics

Identifiers

PMID42034829
PMCPMC13338128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.